Volume 55, Issue 5, Pages 1121-1131 (November 2011) Hepatitis B surface antigen quantification: Why and how to use it in 2011 – A core group report  Henry Lik-Yuen Chan, Alex Thompson, Michelle Martinot-Peignoux, Teerha Piratvisuth, Markus Cornberg, Maurizia Rossana Brunetto, Hans L. Tillmann, Jia-Horng Kao, Ji-Dong Jia, Heiner Wedemeyer, Stephen Locarnini, Harry L.A. Janssen, Patrick Marcellin  Journal of Hepatology  Volume 55, Issue 5, Pages 1121-1131 (November 2011) DOI: 10.1016/j.jhep.2011.06.006 Copyright © 2011 European Association for the Study of the Liver Terms and Conditions

Fig. 1 The HBV open reading frames (ORF), highlighting the overlapping relationship between the envelope ORF and the HBV polymerase ORF. Journal of Hepatology 2011 55, 1121-1131DOI: (10.1016/j.jhep.2011.06.006) Copyright © 2011 European Association for the Study of the Liver Terms and Conditions

Fig. 2 HVB lifecycle. The lifecycle of HBV, highlighting: (i) the nuclear reservoir, covalently closed circular (ccc) DNA, which is the transcriptional template for the virus; (ii) the HBsAg secretory pathways, and (iii) the viral replication pathways. Nucleos(t)ide analogue therapy, by targeting the HBV reverse transcriptase (RT), selectively inhibits virion production, but does not reduce HBsAg levels as cccDNA levels are preserved. IFN-based strategies, which can non-cytolytically clear hepatocytes of HBV cccDNA infection, may therefore induce larger reductions in HBsAg. Journal of Hepatology 2011 55, 1121-1131DOI: (10.1016/j.jhep.2011.06.006) Copyright © 2011 European Association for the Study of the Liver Terms and Conditions

Fig. 3 Flow chart on the use of HBV DNA and HBsAg to predict response to peginterferon treatment in the PARC study. Journal of Hepatology 2011 55, 1121-1131DOI: (10.1016/j.jhep.2011.06.006) Copyright © 2011 European Association for the Study of the Liver Terms and Conditions